SECsense Logo

Adial Pharmaceuticals 8-K Report: Key Insights & Financial Updates (Feb 2025)

$ADIL
Form 8-K
Filed on: 2025-02-25
Source
Adial Pharmaceuticals 8-K Report: Key Insights & Financial Updates (Feb 2025)

Here are the key insights extracted from the provided section of the financial report:

  1. Entity Information:
  • Company Name: Adial Pharmaceuticals, Inc.
  • CIK Number: 0001513525
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 001-38323
  • EIN: 82-3074668
  • Address: 4870 Sadler Road, Ste 300, Glen Allen, VA 23060
  • Phone Number: 804-487-8196
  1. Filing Information:
  • Form Type: 8-K (Current Report)
  • Filing Date: February 25, 2025
  1. Context Details:
  • Report Date: The report provides information as of February 25, 2025.
  • Measurement Units:
    • Financial data presented in US Dollars (USD).
    • Shares are also accounted for, indicating possible share issuance or other equity-related activities.
  1. Stock Information:
  • Common Stock Ticker: ADIL
  • Exchange: NASDAQ
  1. Key Dates:
  • The report period starts and ends on February 25, 2025, indicating a specific event or financial data relevant to that date.

Summary:

This financial report section pertains to Adial Pharmaceuticals, Inc., detailing a current report filed with the SEC (8-K) on February 25, 2025. It provides essential information about the company, including its CIK, stock ticker, and contact details, while also indicating the nature of the financial data (in USD and shares) included in the report. The report is relevant for stakeholders looking for timely updates on the company's financial status or other significant events.